Arterial Network first learned that recently, Beijing Toll Botai Biotechnology Co., Ltd. (hereinafter referred to as: Toll Botai) announced the completion of more than 100 million yuan A round of financing, this round of financing led by Longpan Investment, Zhongguancun Collaborative Innovation Fund, Zhongke Chuangxing, Yuanhui Capital jointly funded, to help Toll Botai research and development of autoimmune diseases of a new class of drugs and the construction of the company's R & D center.
Founded in 2020, Toll Isitel focuses on the development of innovative drugs for autoimmune diseases based on the world's leading Toll-like receptor immune regulatory technology, providing innovative therapies that regulate the human immune response, and solving the pain points of the global immunomodulatory drug market.
Based on the accumulation of nearly 20 years of immune regulatory mechanism research and immunomodulatory drug research, the team has innovatively discovered a new immune regulatory mechanism and a number of world-first immunomodulatory small molecule drugs, and obtained exclusive patents for small molecule drugs, covering the world's major drug research and development countries and regions, forming multiple pipelines and rapidly advancing in the drug research and development of autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and scleroderma.
Toll Botai has now assembled a core team of complementary specialties, including experts in the field of immune regulation, chief physician of the Department of Rheumatology and Immunology of Union Hospital, experts with many years of preclinical and clinical experience, and a number of phDs graduated from internationally renowned universities.
The team will fully promote the clinical research of the company's research projects and continuously enrich the research and development pipeline, determined to overcome the world's problems such as low patient response rate, high price and large side effects of autoimmune disease drugs, make up for the shortcomings and gaps in existing drugs, promote the high-quality growth of the drug market, solve real problems for patients, and inject innovative vitality into the research of national first-class new drugs.
Toll PATEO recently built a new drug research and development platform in the Life Science Park Medical Center, which is expected to be completed and settled in April, based on the perfect pharmaceutical R&D environment and resources of the Life Science Park, to further strengthen Toll PATEO's R&D strength and expand the R&D pipeline.
Mr. Yu Zhihua, Partner of Longpan Investment, said: "Longpan Investment is committed to encouraging and supporting the drug research and development of first-in-class products to provide more treatment options for patients around the world. With Professor Yin Hang as the core, Toll Botai has a global unique core technology research and development platform of highly selective TOLL-like receptor small molecule inhibitors, and believes that it will soon provide more oral small molecule drugs for patients with autoimmune diseases to improve their symptoms and prognosis. ”
Wang Jianjun, managing partner of Zhongguancun Collaborative Innovation Fund, said: "The market has been looking for autoimmune disease drugs with high response rate, small side effects and close prices, and TOLL-like receptor small molecule inhibitors are an important technical route. The Toll Team has a deep understanding of the regulatory immune system, efficient execution and continuous development capabilities, and the whole team is full of vitality and innovation, and is rapidly advancing the productization of multiple pipelines. We look forward to Bringing Roberto's innovative medicines to inject new life into the market and benefit patients as soon as possible." ”
Lei Mi, Founding Partner of Zhongkechuangxing, said: "It is a great honor to participate in Toll Botai's Series A financing. The number of autoimmune diseases is relatively large, the disease heterogeneity is strong, and the diagnosis rate is low, the treatment rate is low, and the drug penetration rate is low, and there are large unmet clinical needs and a broad market space. Based on in-depth research and deep understanding of the mechanism of natural immune regulation, Toll Botai has developed a series of self-immune innovative drugs from the perspective of clinical needs, and has formed a perfect team covering scientific research, industry and clinical. We very much recognize the innovative scientific research achievements of toll Botai team, and look forward to the company's continuous efforts in the future to promote the independently developed innovative drugs to the clinic as soon as possible, bringing the gospel to many self-explanatory patients in China. ”
Fan Zhang, Founding Partner of Yuanhui Capital, said: "We are very optimistic about the Toll-Botai team, which has a unique advantage in exploring the potential of proprietary medicines based on nearly 20 years of continuous research on Toll-like receptor targets and international leading research results. We are optimistic about the company's layout on the pipeline, and look forward to continuous breakthroughs under the unremitting efforts of the team to make science and technology benefit mankind. We will continue to cooperate with and support the long-term development of the company, and actively play the advantages of Yuanhui Capital to promote the company to create greater social value. ”
Gao Meng, Chief Operating Officer of Toll Botai, said: "Toll Botai actively responds to the call of the state to develop a new class of drugs, pays attention to the autoimmune diseases that affect the quality of life of patients in the field of chronic diseases, and actively promotes the research and development of small molecule drugs with new targets and new mechanisms in view of the pain points that need to be solved in the field of diseases, combined with The great advantages of Toll Botai in research and development. We will integrate resources from all walks of life, accelerate the preclinical research and clinical research of key products, further expand products and pipelines, and solve health problems for the majority of sick people. We are very grateful to Longpan Investment, Zhongguancun Collaborative Innovation Fund, Zhongke Chuangxing, Yuanhui Capital and other outstanding capital in the industry for their recognition and support, and also thank Chang Development for their help in this round of financing. We are willing to work with the elites from all walks of life to create a new milestone in the field of autoimmune disease drugs. ”
About Longpan Investment
Headquartered in Beijing, Longpan Investment is a leading biomedical venture capital firm in China. At present, Longpan Investment is managing 4 RMB funds and 1 US dollar fund, with a total scale of more than RMB 6 billion, which is the only biomedical special fund fund funded by the National Social Security Fund so far. Longpan Investment focuses on investing in high-quality projects in the field of innovative drugs and innovative medical devices, and the investment stage is mainly in the start-up stage, early and medium-term. It has invested in more than 50 innovative pharmaceutical enterprises and more than 10 innovative medical device enterprises, including Beida Pharmaceutical, Rongchang Biological, Clover Biological, Yahong Pharmaceutical, Si Microorganism, Binhui Biological, Yiming Onke, Huahao Zhongtian, Aibo Nord and many other star projects. The partners of Longpan Investment Management Team have more than 20 years of R&D and management background in the international/domestic biomedical industry, and can provide comprehensive value-added services for invested enterprises.
About the Zhongguancun Collaborative Innovation Fund
Beijing Zhongguancun Collaborative Innovation Investment Fund Management Co., Ltd. is a holding subsidiary of Zhongguancun Development Group, the first market-oriented fund management company of Zhongguancun Development Group and the only main platform for fund cooperation in cooperation areas. Up to now, the company has managed 13 funds with a fund size of 6 billion yuan, and has achieved good economic and social benefits. The direct investment fund project database has accumulated more than 4,000 hard innovation enterprises, and the Zhongguancun Collaborative Innovation Fund has a total of 178 investment projects, focusing on the four hard technology fields of new generation information technology, high-end manufacturing, medical health and energy conservation and environmental protection. The company inherits the zhongguancun development group technology preference of the goodwill investor concept and the core investment strategy of "hard technology, hard team, hard market", and strives to achieve the dual goals of serving the national scientific and technological innovation development strategy and promoting the growth of capital value.
About Zhongke Chuangxing
Zhongke Chuangxing is China's first professional platform focusing on hard technology venture capital investment and incubation. As the founder of the concept of "hard technology" and the forerunner of "hard technology" investment, Zhongke Chuangxing is committed to creating a hard technology entrepreneurship ecosystem integrating "research institutions + angel investment + entrepreneurial platform + incubation services", providing professional, in-depth and comprehensive investment, incubation and financing solutions for technology entrepreneurs. At present, Zhongke Angel Phase I, Xike Angel Phase II, Xike Angel Phase III, Big Data Incubation Fund, Big Data Industry Fund, Xi'an Zhongke Growth Fund, Shaanxi Optoelectronics Integration Fund, Beijing Hard Technology Venture Capital Fund, Beijing Zhongke Chuangxing Hard Technology Phase II Fund and other funds have been operated, with a total scale of 5.3 billion yuan.
About Source Wise Capital
Founded in 2010, Yuanhui Capital looks for entrepreneurial entrepreneurs with feelings and growing enterprises with hard technology from a long-term perspective, invests in and accompanies the growth of enterprises; promotes the upgrading of enterprises to "business to good" with the concept of "ESG investment" - from "never doing evil and legal operation" to "high-quality sustainable development"; through the model innovation of "venture capital + funded foundation + modern grassroots public welfare", let business continue to empower public welfare hematopoiesis, while promoting the development of modern grassroots public welfare undertakings, Help enterprises achieve greater social welfare value. In the past 11 years since its establishment, Yuanhui Capital has focused on the layout of medical medicine, chip industry and new energy in three major fields, and has invested in more than 50 high-quality enterprises, typical cases include Sannuo Bio, Jiankai Technology, Haijieya, Xiantong Pharmaceutical, Saifu Gene, Kangyuan Bochuang, Yinnuo Pharmaceutical, Tuban Medical, Huagong Biological, etc. in the semiconductor field, Zhuosheng Microelectronics, Montage Technology, Gaotuo Xunda, Mingtai Electronics, Core Power and Najing Technology in the field of medical and pharmaceuticals, Shichuang Energy, Yihong Intelligent, Shenli Technology, etc. in the field of new energy. It belongs to the field of AI and big data, such as Ying Spectral Technology, Quzhi Technology, Liangfengtai, Bangbangxing and Aishu Information.